Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Proteasome inhibitor].

Hideo Yagi

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |July 15, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Proteasome inhibitors, like bortezomib, are crucial for targeting cancer cells by blocking protein degradation. Newer agents show promise in treating multiple myeloma, offering improved efficacy and safety.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diffuse Large B-cell Lymphoma Arising in a Patient with the Long-term Remission of Left-sided Ulcerative Colitis: A Case Report.

    Internal medicine (Tokyo, Japan)·2026
    Same author

    Recurrent Thrombocytopenia During Caplacizumab Therapy in Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura.

    American journal of hematology·2025
    Same author

    Prognostic relevance of early clinical and laboratory findings in immune-mediated thrombotic thrombocytopenic purpura.

    Research and practice in thrombosis and haemostasis·2025
    Same author

    Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum.

    Hematology (Amsterdam, Netherlands)·2025
    Same author

    Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions.

    International journal of hematology·2025
    Same author

    The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.

    Annals of hematology·2024
    Same journal

    [Development of novel therapeutics for multiple myeloma and improvement of drug lag].

    Nihon rinsho. Japanese journal of clinical medicine·2019
    Same journal

    [Clinical pharmacy services to patients of immunomodulatory drugs].

    Nihon rinsho. Japanese journal of clinical medicine·2019
    Same journal

    [Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

    Nihon rinsho. Japanese journal of clinical medicine·2019
    Same journal

    [Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

    Nihon rinsho. Japanese journal of clinical medicine·2019
    Same journal

    [The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

    Nihon rinsho. Japanese journal of clinical medicine·2019
    Same journal

    [Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

    Nihon rinsho. Japanese journal of clinical medicine·2019
    See all related articles

    Area of Science:

    • Cell Biology
    • Molecular Biology
    • Oncology

    Context:

    • The ubiquitin-proteasome system regulates eukaryotic intracellular protein degradation, vital for cell cycle and growth.
    • Cancer cells exhibit elevated proteasome activity, making it a therapeutic target in oncology.
    • Bortezomib, a proteasome inhibitor, is approved for multiple myeloma (MM) treatment.

    Purpose:

    • To review the role of proteasome inhibition in cancer therapy.
    • To discuss the clinical application and development of proteasome inhibitors in multiple myeloma.

    Summary:

    • Proteasome inhibition is a validated strategy in oncology, particularly for multiple myeloma.
    • Bortezomib, the first-in-class proteasome inhibitor, is effective alone and in combination therapies.

    Related Experiment Videos

  • Second-generation inhibitors like carfilzomib and MLN9708 demonstrate positive efficacy and safety in frontline MM treatment.

    • Impact:

    • Proteasome inhibitors offer a targeted approach to cancer treatment.
    • Advancements in proteasome inhibitor therapy are expanding treatment options for multiple myeloma patients.
    • Upcoming approvals of novel proteasome inhibitors are anticipated to further improve patient outcomes.